Estrogen Shapes Fibroblast States to Limit Pancreatic Cancer Aggressiveness

Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extensive desmoplastic stroma that profoundly influences tumor biology and therapeutic response. Cancer-associated fibroblasts (CAF), the major stromal component, exist as heterogeneous populations with both tumor-promoting and tumor-restraining functions. In this issue of Cancer Research, Manoukian and colleagues uncover a previously unrecognized hormonal axis in PDAC, demonstrating that estrogen signaling reprograms fibroblast identity and shapes the tumor microenvironment. Building on prior work identifying an inflammatory CAF subset marked by high OGN and CLEC3B expression (iCAF.1) and associated with favorable prognosis, the authors show that estrogen produced by cancer cells promotes this tumor-restraining phenotype while limiting myofibroblastic CAF activation. Reciprocally, CAF-derived branched-chain amino acids taken up by cancer cells via SLC25A44-mediated uptake fuel estrogen biosynthesis, creating a feedback loop that sustains the classical, less aggressive PDAC subtype. Collectively, these findings establish estrogen as a key modulator of CAF heterogeneity and highlight a novel mechanism of tumor-stroma cross-talk with potential therapeutic implications for stroma-directed interventions in pancreatic cancer. See related article by Manoukian et al., p. 571.